Definium Therapeutics (DFTX): Commodore Capital discloses 2.41M-share, 1.8% beneficial stake
Definium Therapeutics, Inc. (DFTX) said Commodore Capital and related filers reported a Schedule 13G showing beneficial ownership of 2,410,000 common shares, including 410,000 shares issuable from a pre-funded warrant, as of June 30, 2026. The stake equals 1.8% of 134,365,950 shares outstanding, with shared voting and dispositive power.
How this was made
The 30-second read
Why it matters
Disclosed beneficial ownership increases transparency on who holds economic exposure and voting rights, which can affect liquidity and sentiment, but the text does not describe any new corporate action, deal, or operational update.
Market read
Traders may monitor for follow-on activity (exercise of pre-funded warrants or further ownership changes), but the article itself is primarily a disclosure update.
What to watch
Pre-funded warrant exercisability could matter if the company later raises capital or if the holder exercises, but the article does not provide exercise timing, strike price, or any new financing plan.
Background
The article summarizes a Schedule 13G beneficial ownership amendment (No. 3) for Definium Therapeutics, filed by Commodore Capital and related filers.
Ticker impact
Commodore Capital disclosed a 2,410,000-share beneficial stake, including 410,000 shares via pre-funded warrants, representing 1.8% of DFTX.
Likely limited, with potential short-term volatility around ownership-follow-through rather than a sustained directional move.
The filing updates disclosed ownership (2.41M shares, 1.8%) and includes warrant-linked shares, but provides no new business, financing terms, or governance outcome in the text.
Market effects
Minimal sector read-through; this is a single-company ownership disclosure without sector-wide regulatory or clinical implications.
None indicated.
None indicated.
Counterpoint
The stake is only 1.8% and voting/dispositive power is shared, so it may not translate into meaningful influence or follow-on buying pressure.
Key entities
- issuerDefinium Therapeutics, Inc.
Subject of the Schedule 13G beneficial ownership disclosure summarized in the article.
- investorCommodore Capital LP
Reporting person disclosing beneficial ownership of 2,410,000 common shares (shared voting/dispositive power).
- investorCommodore Capital Master LP
Related reporting person included in the beneficial ownership group.
- investorRobert Egen Atkinson
Individual reporting person included in the beneficial ownership disclosure.
- investorMichael Kramarz
Individual reporting person included in the beneficial ownership disclosure (mentioned in the article text).
